Documente Academic
Documente Profesional
Documente Cultură
• 1. Infectioase : a. Bruceloza
b.Tuberculoza
c. Histoplasmoza
d. Candidioza
e. Schistosomiaza
f. Febra Q
2. Imunologice a. Sarcoidoza
b. Ciroza biliara primitiva
3. Medicamentoase a. Difenilhidantoina
b. allopurinolul
4. Neoplasme a. limfoame
b. carcinoame
Hepatite medicamentoase
Normal Troglitazone
Biseptol La 2 luni
Didanozona
Acetaminofen
Lobul hepatic normal Sulfasalazina
Estradiol Metildopa
Amiodarona Metotrexat
• Istoric
• 1948 Wood Hepatita Cronica Infectioasa
• 1950 Waldenstrom noteaza predispozitia feminina
• 1951 Kunkel hepatita cu hiperglobulinemie
• 1955 Mackay le denumeste “Lupoida”
• 1957 Rezultatele Corticoterapiei
• 1968 Clasificarea histologica
• 1969 Mistilis si Blackburn introduc Imunosupresa
• 1974 Modificarea clasificarii histologice
• 1994 Clasificarea etiologica
HEPATITE CRONICE DIFUZE
• Prioritati romanesti :
Clinica :
1. Astenie fizica
2. Icter
3. Hepatomegalie
Anomalii Biochimice
• 1. Cresterea aminotransferazelor este
anomalia princeps
• 2. Raportul
ASAT/ALAT > 2 - leziune
alcool indusa
ASAT/ALAT < 1 - leziune
viral indusa
Anomalii biochimice tipice in boli
Hepatobiliare
•
Aspecte Morfologice
• 1. Limfocite
• 2. Plasmocite
• 3. Macrofage
Inflamatia Periportala
• 1. Se insoteste de necroza
• 2. Este variabila
• 3. Are anomalii nucleare
• 4. Determina grading - ul
Fibroza
• 0 absenta
• 1 blanda periportala
• 2 moderata portoportala
• 3 severa portocentrala
• 4 ciroza
HEPATITE CRONICE DIFUZE
• Clasificare etiologica
• 1. AUTOIMUNA
• 2. VIRALA B
• 3. VIRALA B cu D
• 4. VIRALA C
• 5. MEDICAMENTOASA
• 6. BOALA WILSON
• 7. DEFICIT A1AT
• 8. CRIPTOGENETICE
Hepatite
cronice
Causes of viral hepatitis
Hepatitis Common Transmission routes Infection
virus name
A Infectious hepatitis Enteral Acute only
Envelope
containin
g
HBsAg
DNA polymerase
Double-stranded
DNA
Single-stranded
DNA
HBcAg
(HBeAg)
Hepatitis B Antigens
Hepatitis B surface antigen (HBsAg)
• First serological marker to appear
• Persistence for >6 months = chronic infection
IgM anti-HBc
Never Been Exposed to
Hepatitis B
No viral markers
No immune response to the
– HBsAg - virus
– HBeAg - Anti-HBc -
– HBV DNA - Anti-HBs -
Anti-HBe -
Acute Hepatitis B
HBsAg +
– Anti-HBc +
for 6 months
– Anti-HBs -
HBeAg -
– Anti-HBe +
HBV DNA -
• Therapy selection
• Monitoring
– virological response to therapy
– disease progression
– HBV replication after liver transplantation
HBV DNA Assays
IgM anti-HBc
0 4 8 12 16 20 24 28 32 36 52 Years
Weeks after Exposure
IMUNOPATOGENEZA
Boli extrahepatice:
• 1. Poliarterita nodoasa
• 2. GN Membranoasa / Membranoproliferativa
• 3. Vasculita Leucocitoclazica
• 4. Crioglobulinemie
Possible outcomes of infection
with hepatitis B virus
Transient
Subclinical 65%
100% Infection
Acute
HBV
Recovery Infection
99% 25%
Acute
Hepatitis
99% 25%
Acute
Hepatitis
1%
Fulminant
Hepatitis
99% 25%
Acute
Hepatitis
1%
Fulminant
Hepatitis
Resolution
Chronic
Infection
70-90%
Asymptomatic
Chronic Carrier
Inactive
Resolution Resolution Resolution
Cirrhosis
10-30%
Chronic Chronic HCC
Cirrhosis Dysplasia
Infection Hepatitis
70-90%
Chronic Carrier
STADIUL 1 2 3 4
AgHBs + + + -
Anti HBs - - - +
HBV DNA ++ + - -
Anti HBc + + + +
Ag HBe + + - -
Anti HBe - - + +
ALAT N crescut N N
Hepatitis B - Clinical Features
• Yellow discolouration
of:
– Skin
– Mucous membranes
– Sclera of the eyes
Assessing Severity of Liver
Disease in Hepatitis B
• Mild
Raised ALT and/or AST only
• More severe
Raised ALT/AST and raised bilirubin
• 1987 Rizzeto
• Virus ARN
• Necesita HBV care furnizeaza :
1. Nucleocapsida
2. Anvelopa
Survine :
1. Coinfectie
2. Suprainfectie
Important de cautat la:
1. Bolnavii ce se agraveaza
2. Bolnavii AgHBe negativi
Infectare :
1. Parenterala
2. Intrafamiliara
HEPATITA C
• Clasificarea in 6 tipuri:
1a
1b (90% in Romania)
2a
2b
3a
4a
Produce cvasispecii-impiedicand realizarea unui
vaccin .
Distributia geografica: 1a,b SUA, Euroa
1b,2a,2b Japonia
3 Thailanda, Australia,
Europa de nord
4.Asia
5.Africa de Sud
6. Hong Kong
• Epidemiologie:
• 1,4 % din populatia generala
• 0,1-0,7 %donatori
• 4-6 % Africa, Orientul Mijlociu
• Creste cu varsta 0,2-3,9 %
• Dializati 20 %
• Hemofilicii 65 %
• Narcomanii 70 %
• Personalul medical 0-10 %
• TRANSMISIE:
• 40-50% droguri intravenoase
• 5-25% transfuzii
• CAI DE TRANSMISIE:
• ace - droguri
• - personal medical
• hemodializa 2-3%
• tatuaje
• transfuzie – sange
• - produse 0,1%
• sexual
• intrafamilial
• 50% cai necunoscute
Manifestari clinice
1. Simptome mai blande
2. Multi asimptomatici
3. 25 % icter
DIAGNOSTIC
I NESPECIFIC 1. Anamneza factori de risc
2. ALAT
III HISTOLOGIC
COINFECTIA B cu C
1. S. Sjögren
2. Crioglobulinemie
3. Porfiria acuta tarda
4. Limfoame non - hodgkiniene
DECIZIA DE TRATAMENT
ESTE DEPENDENTA DE:
I. GRADUL DE ACTIVITATE AL BOLII
- absenta cirozei
- fibroza redusa
IV. RISCURI
- legate de terapie
boli autoimune
rezistenta la tratament
- legate de teren
transplantatii
V. CONTRAINDICATII
(in principal pentru IFN)
1. Epilepsie
2. Psihoze
3. Citopenii
4. Ciroze
5. Graviditate
6. Comorbiditati grave - a). Insuficienta cardiaca
b). Insuficienta renala
c). Diabet
d). Poliartrita reumatoida
SCOPUL TRATAMENTELOR
1. Diminuarea necroinflamatiei
2. Reducerea fibrozei
1. Varsta 65 ani
2. ALAT > 2 N, peste 6 luni
3. Semne de replicare virala
4. IAH 6 KNODELL
FACTORII PREDICTIVI DE
BUN AUGUR
NU sunt contraindicatii
1. Prezenta anti LKM1 (5%)
2. Coinfectia cu virus G
FACTORII FAVORABILI DE
EVOLUTIE
1. Durata scurta a bolii
2. Genotipurile 2, 3
3. Viremie redusa < 2x106 copii/mL
4. Complexitate redusa a HVR 1
5. Absenta fibrozei
6. Sex feminin
7. Varsta < 40 ani
8. Sistem imun - T/B crescut
- CD11-, CD8+ reduse
FACTORII PREDICTIVI CU
INFLUENTA NEGATIVA
1. Genotipul 1
2. Sarcina virala mare
3. Variabilitate mare
4. Sex masculin
5. Varsta > 40 ani
6. Coinfectia HIV, HVB
7. Obezitate
8. Incarcare cu fier (hepatocitara, serica)
HEPATITA CRONICA D
Se supune criteriilor hepatitei B, la care
se adauga:
- anti HVD
- ARN viral
INTERFERONII
R R
mesager
Efecte antitumorale
ARN
proteina
Imunomodulatoare
- citokine
- C2
- activare celulara
MOD DE ACTIUNE
EFECTE ADVERSE
1. Constitutionale
2. Hematologice
3. Neuropsihiatrice
4. Autoimune - ANA
- SMA
- Antitiroidieni
ANALOGI NUCLEOZIDICI
1. LAMIVUDINA
2. RIBAVIRINA
3. ACICLOVIR
4. FAMCICLOVIR
5. ADENINARABINOZID
6. GANCICLOVIR
HEPATITE AUTOIMUNE
Hepatita cronica, predominent periportala cu hiper globulinemie si autoanticorpi tisulari
care raspunde la tratamentul imunosupresor, cel mai frecvent.
I II III
1. B. WILSON - ceruloplasmina
- excretia urinara de cupru
- examen oftalmologic
- cupru hepatic
2. Hemocromatoza - sideremie
- transferina
- depozite de fier hepatic
1. Titrul anticorpilor
2. PCR HVC
Scorul diagnostic
ITEM PUNCTE
1. Sex F 2
2.F.A./ALT <1,5 = +2; >3 = -2
3.IgG >2N=3 ; <1N = 0
4.Autoanticorpi >1/80 = 3pct
5.AMA - 3 pct
6.Markeri virali +/- 3 pct
7.Medicamente - = 3 / + =4 pct
8.Alcool < 25g/zi = +2 pct
9.Histologie Piece-meal = 3 pct
10.Boli autoimune +2 pcte
11.Raspuns la tratament +2 pcte
SEMNIFICATIE
PRETRATAMENT PUNCTEH
POSTTRATAMENT
• Tacrolimus 4 mg x 2/zi
• Imunoglobuline
ALTI AGENTI :
1. CICLOSPORINA 5 mg / kcorp
2. TACROLIMUS 4 mg / zi
3. AC URSODESOXICOLIC 250 – 750 nesigur
4. TIMOZINA descurajant
5. FOSFATIDILCOLINA + CORTICOIZI